Aghazadeh Behzad
SEC insider (Form 3/4/5 filer). CIK 0001701815. Director at Scribe Therapeutics, Inc. (SCTX) and 1 other issuer. 7 reported Form 4/5 transactions since Sep 2024; latest on Jul 28, 2026. Located in NEW YORK, NY.
Companies Aghazadeh Behzad has filed insider reports for
- Scribe Therapeutics, Inc. (SCTX): Director
- Whitehawk Therapeutics, Inc. (WHWK): Director, 10% Owner
Aghazadeh Behzad
CIK: 0001701815
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (7 total)
- Jul 28, 2026SCTX
Scribe Therapeutics, Inc.
PurchaseIndirect7.9K shares at avg. $18.25$144K - Jul 24, 2026SCTX
Scribe Therapeutics, Inc.
PurchaseIndirect50K shares at avg. $22.31$1.1M - Jul 24, 2026SCTX
Scribe Therapeutics, Inc.
PurchaseIndirect2.3M shares at avg. $15.00$35.0M - Jul 23, 2026SCTX
Scribe Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
14.7K shares- - Jun 12, 2026WHWK
Whitehawk Therapeutics, Inc.
AwardDirectStock Option (right to buy)
38K shares- - Jun 12, 2025WHWK
Whitehawk Therapeutics, Inc.
AwardDirectStock Option (right to buy)
40K shares- - Feb 28, 2025AADI
Aadi Bioscience, Inc.
AwardIndirectPre-funded Warrant (right to buy)
8.3M shares at avg. $2.40-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 28, 2026 |  SCTX Scribe Therapeutics, Inc. | Purchase | 7,905 | $18.25 | $144,266 | Indirect |
| Jul 24, 2026 | SCTX Scribe Therapeutics, Inc. | Purchase | 50,000 | $22.31 | $1,115,500 | Indirect |
| Jul 24, 2026 | SCTX Scribe Therapeutics, Inc. | Purchase | 2,333,333 | $15.00 | $34,999,995 | Indirect |
| Jul 23, 2026 | SCTX Scribe Therapeutics, Inc. | Award Stock Option (Right to Buy) | 14,725 | - | - | Direct |
| Jun 12, 2026 |  WHWK Whitehawk Therapeutics, Inc. | Award Stock Option (right to buy) | 38,040 | - | - | Direct |
| Jun 12, 2025 | WHWK Whitehawk Therapeutics, Inc. | Award Stock Option (right to buy) | 40,006 | - | - | Direct |
| Feb 28, 2025 |  AADI Aadi Bioscience, Inc. | Award Pre-funded Warrant (right to buy) | 8,333,000 | $2.40 | - | Indirect |
1-7 of 7 transactions